Polymorphisms of the GSTT1 and GSTM1 genes in women of central Serbia: Absence of association with uterine myoma by Arsenijević S. et al.
Arch. Biol. Sci., Belgrade, 65 (2), 415-420, 2013 DOI:10.2298/ABS1302415A
415
POLYMORPHISMS OF THE GSTT1 AND GSTM1 GENES IN WOMEN OF  
CENTRAL SERBIA – ABSENCE OF ASSOCIATION WITH UTERINE MYOMA
S. ARSENIJEVIĆ1, BILJANA LJUJIĆ2, IVANA STOŠIĆ3, D. GRUJIČIĆ3, D. MARINKOVIĆ4 and  
OLIVERA MILOŠEVIĆ- DJORDJEVIĆ1, 3,*
1 Faculty of Medicine, University of Kragujevac, 34000 Kragujevac, Serbia 
2 Center for Molecular Medicine and Stem Cell Research, Faculty of Medicine, University of Kragujevac,  
34000 Kragujevac, Serbia 
3 Faculty of Science, University of Kragujevac, 34000 Kragujevac, Serbia 
4 Serbian Academy of Sciences and Arts, 11000 Belgrade, Serbia
Abstract - Since glutathione S-transferase (GST) enzymes are involved in cellular protection, we aimed to determine the 
distribution of GSTT1 and GSTM1 null genotypes in women in central Serbia in order to assess the risk of development 
of uterine myoma. The study consisted of 34 clinically diagnosed uterine myoma patients and 35 healthy control women. 
Analyses of GST polymorphism were carried out by multiplex PCR. Our results showed no significant differences in the 
GSTT1 and GSTM1 null genotypes between the patients and controls. Using the GSTT1 positive/GSTM1 positive combi-
nation as reference, there was no statistically significant risk of uterine myoma with the combination of GSTT1 null and 
GSTM1 null genotypes. We conclude that polymorphism of both GSTT1 and GSTM1 genes, alone or in combination, did 
not present the main risk for uterine myoma in women from central Serbia.
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INTRODUCTION
Uterine myoma is one of the most common benign 
tumors, occurring in 20-40% of women in their re-
productive years (Duhan, 2011). The precise etiol-
ogy of this tumor is not clear and some of the pos-
sible factors that promote the development and the 
growth of myoma, as well possible risk factors, have 
been reviewed by Parker (2007).
In  order  to  better  understand  the  molecular 
pathway of diseases, polymorphisms of the enzymes 
involved in cellular protection have long been evalu-
ated. So far, the greatest interest has been focused on 
GST enzymes, a large family of xenobiotic-detoxify-
ing phase II enzymes, which take part in the conju-
gation of endogenous and exogenous electrophiles 
and play an important role in the detoxification of 
several toxic and carcinogenic substances (Clapper, 
2000). Deletion variants or null alleles exist for both 
GSTT1 and GSTM1 genes which are presented bio-
chemically as a failure to express protein (McIlvan 
et al., 2006). Numerous studies have investigated the 
role of GST polymorphisms in the increased risk for 
predisposition to various cancers, including bladder 
(Salagovic et al., 1999), oral (Zhang et al., 2011), uter-
ine cervical (Wang et al., 2011), gastric (Chen et al., 
2010), prostate (Srivastava et al., 2005), endometrial 
(Karageorgi et al., 2011) and other diseases such as 
type 2 diabetes mellitus (Bid et al., 2010), neurologi-
cal diseases (Stroombergen and Waring, 1999) and 
male infertility (Safarinejad et al., 2010). 416 S. ARSENIJEVIĆ ET AL.
The aim of the present study was to determine 
the distribution of GSTT1 and GSTM1 null poly-
morphisms  in  women  in  central  Serbia  with  and 
without uterine myoma in order to assess the risks 
presented by individual and combined genotypes in 
the development of uterine myoma. To the best of 
our knowledge, this is the first study of the incidence 
of GSTT1 and GSTM1 polymorphisms among pa-
tients from central Serbia with clinically diagnosed 
uterine myoma. 
MATERIALS AND METHODS
Subjects
The case-control study population consisted of 34 
uterine myoma patients (aged from 32 to 71) with 
both ultrasound and histological diagnosis of uterine 
myoma, and 35 healthy control women without any 
kind  of  gynecological  abnormality  or  malignancy 
(aged from 24 to 58). Patients were recruited during 
2010 and 2011 at the Clinic of Obstetrics and Gyne-
cology in the Clinical Center Kragujevac (Kraguje-
vac, Serbia). Blood samples were collected for DNA 
extraction. 
This study was approved by the Ethics Commit-
tee of the Clinical Center Kragujevac (No 01 - 100).
GSTT1 and GSTM1 genotyping
Genomic DNA from patients and healthy controls 
was extracted from whole peripheral blood using an 
EZ1 DNA Blood 350 µl Kit (Qiagen, Hilden, Germa-
ny) and BioRobot EZ1(Qiagen, Hilden, Germany). 
GSTT1 and GSTM1 genotyping for gene dele-
tions was carried out by the multiplex polymerase 
chain  reaction  described  by  Abdel-Rahman  et  al. 
(1996), with some modification. DNA samples were 
amplified with the primers: 5’ - TTCCTTACTGGTC-
CTCACATCTC-  3’  and  5’  -  TCACCGGATCAT-
GGCCAGCA – 3’ for GSTT1, which produced a 480 
bp product; 5’ - GAACTCCCTGAAAAGCTAAAGC 
– 3’ and  5’- GTTGGGCTCAAATATACGGTGG- 3’ 
for GSTM1, which produced a 215 bp product. Am-
plification of exon 7 of CYP1A1 with the primers 
5’-  GAACTGCCACTTCAGCTGTCT–  3’  and  5’- 
CAGCTGCATTTGGAA  GTGCTC - 3’  was used as 
an internal control and produced a 312 bp product. 
PCR was performed in a final volume of 50 µl con-
sisting of 30 pmol of primers for GSTT1, GSTM1 and 
CYP1A1 primers (Invitrogen, California, USA), 200 
μM of dNTP (Invitrogen, California, USA), 1.5mM 
of MgCl2, 1X PCR buffer and 2U of Taq polymerase 
(Invitrogen, California, USA), glycerol and 5% dime-
thyl sulfoxide (DMSO). PCR was performed with an 
initial denaturation at 94oC for 5 min, followed by 35 
cycles of amplification at 94oC for 2 min, annealing at 
58oC for 1 min and extension at 72oC for 1 min. The 
final extension was performed at 72oC for 10 min. 
The  amplified  products  were  visualized  in  2% 
agarose gel using SYBR Safe DNA gel stain (Invit-
rogen, California, USA). Bands of 480 bp and 215 
bp correspond to GSTT1 and GSTM1 genes, respec-
tively. 
Statistical analysis
The data were analyzed using the statistical pack-
age for social sciences (SPSS) for Windows, version 
11.5. The chi-square (χ2) and Fischer’s (F) exact test 
were used to compare variables between groups. The 
level of significance was taken as p <0.05. The odds 
ratios (OR) with 95% confidence interval (CI) were 
calculated simultaneously as an estimate of the risk 
for uterine myoma in individuals with GSTT1 and 
GSTM1 genotype polymorphisms. 
RESULTS
The distribution of persons and OR for GSTT1 and 
GSTM1 genotypes as well as the GSTT1 and GSTM1 
genotypes in patients and healthy controls, are shown 
in Tables 1 and 2. 
The proportion of persons in the patient sample 
with GSTT1 null genotype was 17.6%. No statistical-
ly significant difference was found between the uter-
ine myoma patients and the healthy control (17.6% 
vs. 34.3%) for the GSTT1 null genotype (Table 1). GST POLYMORPHISM AND UTERINE MYOMA 417
The GSTT1 null genotype did not increase the risk of 
uterine myoma development (OR = 0.41, 95% CI = 
0.13-1.26, p = 0.12)
The  proportion  of  patients  with  GSTM1  null 
genotype was 73.5% and in the control sample it was 
62.9%. No significant difference was found between 
the uterine myoma patients and healthy controls for 
the GSTM1 null genotype (p = 0.342) (Table 1). The 
GSTM1 null genotype did not increase the risk of 
uterine myoma development (OR = 1.64, 95% CI = 
0.59-4.57, p = 0.34).
Considering  different  combinations  of  GSTT1 
and GSTM1 genes among the uterine myoma pa-
tients, 14.7% (5/34) were homozygous GSTT1 null/
GSTM1 null genotypes. Among the controls, 20% 
(7/35) were homozygous GSTT1 null/GSTM1 null; 
this was statistically non-significant in comparison 
to the patient sample.
The  distribution  of  a  GSTT1  positive/GSTM1 
null combination of genotypes was the highest in 
both  patients  and  controls  (58.8%  vs.  42.9%).  No 
statistically significant difference was found between 
the uterine myoma patients and the healthy controls 
for this combination of genotypes (p = 0.634). 
Table 2 shows the OR of uterine myoma asso-
ciated with each combination of genotypes. Using 
the  GSTT1  positive/GSTM1  positive  combination 
of genotypes as reference, there were no statistically 
 
Fig. 1. Electrophoresis of the multiplex PCR amplified products showing individuals for the GSTT1 and GSTM1 polymorphisms. Ho-
mozygous: line 3 GSTT1 positive/GSTM1 positive genotypes, and line 5 GSTT1 null/GSTM1 null genotypes; Heterozygous: lines 1, 2 
and 6 GSTT1 positive/GSTM1 null genotypes, and line 4 GSTT1 null/GSTM1 positive genotypes 418 S. ARSENIJEVIĆ ET AL.
significant risk of uterine myoma with the combina-
tions of the GSTT1 and GSTM1 null genotypes (OR 
= 1.33, 95% CI = 0.41-4.37, p = 0.63; OR = 0.20, 95% 
CI = 0.02-2.11, p = 0.18; OR = 0.71, 95% CI = 0.16-
3.23, p = 0.66). 
DISCUSSION
In the relevant literature there are a number of stud-
ies that evaluate the polymorphism of GSTT1 and 
GSTM1  genes  and  its  association  with  different 
gynecologic diseases – endometriosis ( Baranova et 
al., 1999; Hur et al., 2004; Aban et al., 2004), poly-
cystic  ovaries  (Babu  et  al.,  2004),  cervical  cancer 
(Sharma et al., 2004; Kiran et al., 2010), ovarian can-
cer (Spurdle et al., 2001), breast cancer (Gudmunds-
dottir et al., 2001; Ramalhinho et al., 2011). When 
it comes to uterine myoma, there is a study that in-
vestigated the relationship of GSTM1 polymorphism 
with susceptibility to this common disease (de Ol-
iveira et al., 2009). However, in addition to GSTM1 
gene polymorphism, a few recent studies have been 
investigating the relationship between uterine leio-
myoma and polymorphism of the DNA repair gene 
XRCC1 (Jeon et al., 2005; Yang et al., 2010), CYP1A1 
and CYP1B1 genetic polymorphism (Ye et al., 2008), 
as well CYP1A1 and CYP2A13 polymorphism (Herr 
et al., 2006).
In  the  present  study,  GST  polymorphism  as-
sociated with the risk of uterine myoma in women 
in central Serbia was evaluated using GSTT1 and 
GSTM1 genotyping for gene deletions by multiplex 
polymerase chain reaction. Our results showed no 
significant difference in the frequencies of GSTM1 
null deletions between patients and controls (73.5% 
vs. 63.9%). These data are in agreement with recent 
reported  studies;  no  significant  differences  in  the 
frequency of GSTM1 polymorphism in control and 
uterine leiomyoma patients from Brazil was reported 
by de Oliveira et al. (2009) and in both fibroblas-
tic breast conditions or breast cancer patients and 
healthy controls from China was reported by Sakoda 
et al. (2008). 
Table 1. Distribution of persons and ORs for GSTT1 and GSTM1 genotypes 
Polymorphism Patients (%) Controls (%) p OR 95% CI
GSTT1
positive
null
28 (82.4)
6 (17.6)
23 (65.7)
12 (34.3) 0.116 0.41 0.13 - 1.26
(p = 0.12)
GSTM1
positive
null
9 (26.5)
25 (73.5)
13 (37.1)
22 (62.9) 0.342 1.64 0.59 – 4.57
(p = 0.34)
OR = odds ratio; CI = confidence interval
Table 2. Distribution of GSTT1 and GSTM1 genotypes and ORs in women with and without uterine myoma 
Polymorphism Patients (%) Controls (%) p OR 95% CI
GSTT1/GSTM1
positive/positive
positive/null
null/positive
null/null
8 (23.5)
20 (58.8)
1 (2.9)
5 (14.7)
8 (22.9)
15 (42.9)
5 (14.3)
7 (20.0)
0.634
0.333
0.662
1.33
0.20
0.71
0.41 – 4.37
(p = 0.63)
0.02 – 2.11
(p = 0.18)
0.16 – 3.23
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In our study, no significant difference in the fre-
quencies of GSTT1 null genotypes between uterine 
myoma patients and healthy controls was observed. 
Very recently, Whang et al. (2011) reported the lack 
of association of the GSTT1 null genotype and cer-
vical cancer. Furthermore, similar results have been 
obtained in studies that considered the association 
of  GSTT1  and  GSTM1  polymorphism  and  gyne-
cological diseases. Hur et al. (2004) did not find an 
association  between  the  polymorphism  of  GSTT1 
and GSTM1 and endometriosis in Korean women. 
In endometriosis patients from southeastern Eng-
land the frequency of GSTM1 null was lower than 
in the control (Baxter et al., 2001). Babu et al. (2004) 
reported no significant difference in the frequencies 
of GSTT1 null and GSTM1 null genotypes between 
Indian women with polycystic ovaries and healthy 
controls.
In our study, the combination of carrying the 
GSTT1  null/GSTM1  null  or  GSTT1  null/GSTM1 
positive and GSTT1 positive/GSTM1 null did not 
present an increased risk for uterine myoma in wom-
en from Central Serbia.
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